Leonard John M's Form 4 filing
Intellia Therapeutics, Inc. (NTLA) · filed Dec 12, 2025
- Accession no.
- 0001193125-25-317551
- Filed
- Dec 12, 2025
- Trade date
- Dec 11-12, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $836.4K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard John MCIK 0001563584 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | Common Stock | MOption exerciseAcquired | +49,959 | $6.83 | +$341,219.97 | 1,127,074 | Direct | |
| Dec 11, 2025 | Common Stock | SSaleDisposed | −49,959 | $9.49F2 | −$474,110.91 | 1,077,115 | Direct | |
| Dec 11, 2025 | Common Stock | SSaleDisposed | −32,832 | $9.47F3 | −$310,919.04 | 1,044,283 | Direct | |
| Dec 11, 2025 | Common Stock | SSaleDisposed | −5,355 | $9.59F4 | −$51,354.45 | 1,038,928 | Direct | |
| Dec 12, 2025 | Common Stock | MOption exerciseAcquired | +8,557 | $6.83 | +$58,444.31 | 1,047,485 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | Common Stock | MOption exerciseDisposed | −49,959 | $0.00 | $0 | 8,557 | Direct | |
| Dec 12, 2025 | Common Stock | MOption exerciseDisposed | −8,557 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.